Challenges and opportunities in limiting abdominal aortic aneurysm growth

Journal of Vascular Surgery

Volumn 65, Issue 1, 2017, Pages 225-233

  Golledge, Jonathan ^a,b   Norman, Paul E ^c   Murphy, Michael P ^d   Dalman, Ronald L ^e  

^a JAMES COOK UNIVERSITY   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CYCLOSPORIN A; DOXYCYCLINE; IMMUNOMODULATING AGENT; CARDIOVASCULAR AGENT;

ABDOMINAL AORTA ANEURYSM; ARTERY DIAMETER; BIOMECHANICS; BLOOD VESSEL FUNCTION; CARDIAC IMAGING; CLINICAL TRIAL (TOPIC); CONSERVATIVE TREATMENT; DISEASE COURSE; HEART VOLUME; HUMAN; MAST CELL; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; ABDOMINAL AORTA; ANIMAL; AORTIC ANEURYSM, ABDOMINAL; DIAGNOSTIC IMAGING; DRUG DEVELOPMENT; DRUG EFFECTS; LESIONS AND DEFECTS; PATHOLOGY;

ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; CARDIOVASCULAR AGENTS; DILATATION, PATHOLOGIC; DISEASE PROGRESSION; DRUG DISCOVERY; HUMANS;

EID: 84994713366     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2016.08.003     Document Type: Review

References (64)

1. 1 Sampson, U.K., Norman, P.E., Fowkes, F.G., Aboyans, V., Yanna, S., Harrell, F.E. Jr., et al. Global and regional burden of aortic dissection and aneurysms: mortality trends in 21 world regions, 1990 to 2010. Global Heart 9 (2014), 171–180.
2. 2 Sidloff, D., Stather, P., Dattani, N., Bown, M., Thompson, J., Sayers, R., et al. Aneurysm global epidemiology study: public health measures can further reduce abdominal aortic aneurysm mortality. Circulation 129 (2014), 747–753.
3. 3 Stather, P.W., Sidloff, D.A., Rhema, I.A., Choke, E., Bown, M.J., Sayers, R.D., A review of current reporting of abdominal aortic aneurysm mortality and prevalence in the literature. Eur J Vasc Endovasc Surg 47 (2014), 240–242.
4. 4 Lederle, F.A., The rise and fall of abdominal aortic aneurysm. Circulation 124 (2011), 1097–1099.
5. 5 Nelissen, B.G., Herwaarden, J.A., Pasterkamp, G., Moll, F.L., Vaartjes, I., Shifting abdominal aortic aneurysm mortality trends in The Netherlands. J Vasc Surg 61 (2015), 642–647.
6. 6 Schermerhorn, M.L., Bensley, R.P., Giles, K.A., Hurks, R., O'Malley, A.J., Cotterill, P., et al. Changes in abdominal aortic aneurysm rupture and short-term mortality, 1995-2008: a retrospective observational study. Ann Surg 256 (2012), 651–658.
7. 7 Svensjo, S., Bjorck, M., Gurtelschmid, M., Djavani Gidlund, K., Hellberg, A., Wanhainen, A., Low prevalence of abdominal aortic aneurysm among 65-year-old Swedish men indicates a change in the epidemiology of the disease. Circulation 124 (2011), 1118–1123.
8. 8 Chaikof, E.L., Brewster, D.C., Dalman, R.L., Makaroun, M.S., Illig, K.A., Sicard, G.A., et al. The care of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery practice guidelines. J Vasc Surg 50:4 Suppl (2009), S2–S49.
9. 9 United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 346 (2002), 1445–1452.
10. 10 Cao, P., De Rango, P., Verzini, F., Parlani, G., Romano, L., Cieri, E., Comparison of surveillance versus aortic endografting for small aneurysm repair (CAESAR): results from a randomised trial. Eur J Vasc Endovasc Surg 41 (2011), 13–25.
11. 11 Lederle, F.A., Johnson, G.R., Wilson, S.E., Chute, E.P., Littooy, F.N., Bandyk, D., et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 126 (1997), 441–449.
12. 12 Kent, K.C., Zwolak, R.M., Egorova, N.N., Riles, T.S., Manganaro, A., Moskowitz, A.J., et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg 52 (2010), 539–548.
13. 13 Maegdefessel, L., Dalman, R.L., Tsao, P.S., Pathogenesis of abdominal aortic aneurysms: microRNAs, proteases, genetic associations. Annu Rev Med 65 (2014), 49–62.
14. 14 Dua, M.M., Dalman, R.L., Hemodynamic influences on abdominal aortic aneurysm disease: Application of biomechanics to aneurysm pathophysiology. Vasc Pharmacol 53 (2010), 11–21.
15. 15 Golledge, J., Norman, P.E., Pathophysiology of abdominal aortic aneurysm relevant to improvements in patients' management. Curr Opin Cardiol 24 (2009), 532–538.
16. 16 Emeto, T.I., Moxon, J.V., Au, M., Golledge, J., Oxidative stress and abdominal aortic aneurysm: potential treatment targets. Clin Sci (Lond) 130 (2016), 301–315.
17. 17 Golledge, J., Kuivaniemi, H., Genetics of abdominal aortic aneurysm. Curr Opin Cardiol 28 (2013), 290–296.
18. 18 Golledge, J., Muller, J., Daugherty, A., Norman, P., Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 26 (2006), 2605–2613.
19. 19 Golledge, J., Norman, P.E., Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors?. Arterioscler Thromb Vasc Biol 30 (2010), 1075–1077.
20. 20 Chang, T.W., Gracon, A.S., Murphy, M.P., Wilkes, D.S., Exploring autoimmunity in the pathogenesis of abdominal aortic aneurysms. Am J Physiol Heart Circ Physiol 309 (2015), H719–H727.
21. 21 Golledge, J., Biros, E., Bingley, J., Iyer, V., Krishna, S.M., Epigenetics and peripheral artery disease. Curr Atheroscler Rep, 18, 2016, 15.
22. 22 Tedesco, M.M., Dalman, R.L., Arterial aneurysms. Johnston, K.W., Cronenwett, J., (eds.) Rutherford's vascular surgery, 7th ed, 2010, Saunders Elsevier, Philadelphia, PA, 117–130.
23. 23 Phillips, E.H., Yrineo, A.A., Schroeder, H.D., Wilson, K.E., Cheng, J.X., Goergen, C.J., Morphological and biomechanical differences in the elastase and AngII apoE(-/-) rodent models of abdominal aortic aneurysms. Biomed Res Int, 2015, 2015, 413189.
24. 24 Lindeman, J.H., Rabelink, T.J., van Bockel, J.H., Immunosuppression and the abdominal aortic aneurysm: Doctor Jekyll or Mister Hyde?. Circulation 124 (2011), e463–e465.
25. 25 Wang, X.L., Thompson, M.M., Dole, W.P., Dalman, R.L., Zalewski, A., Standardization of outcome measures in clinical trials of pharmacological treatment for abdominal aortic aneurysm. Expert Rev Cardiovasc Ther 10 (2012), 1251–1260.
26. 26 Wanhainen, A., Mani, K., Golledge, J., Surrogate markers of abdominal aortic aneurysm progression. Arterioscler Thromb Vasc Biol 36 (2016), 236–244.
27. 27 Parr, A., Jayaratne, C., Buttner, P., Golledge, J., Comparison of volume and diameter measurement in assessing small abdominal aortic aneurysm expansion examined using computed tomographic angiography. Eur J Radiol 79 (2011), 42–47.
28. 28 Gasser, T.C., Nchimi, A., Swedenborg, J., Roy, J., Sakalihasan, N., Bockler, D., et al. A novel strategy to translate the biomechanical rupture risk of abdominal aortic aneurysms to their equivalent diameter risk: method and retrospective validation. Eur J Vasc Endovasc Surg 47 (2014), 288–295.
29. 29 Khosla, S., Morris, D.R., Moxon, J.V., Walker, P.J., Gasser, T.C., Golledge, J., Meta-analysis of peak wall stress in ruptured, symptomatic and intact abdominal aortic aneurysms. Br J Surg 101 (2014), 1350–1357.
30. 30 Courtois, A., Nusgens, B.V., Hustinx, R., Namur, G., Gomez, P., Somja, J., et al. 18F-FDG uptake assessed by PET/CT in abdominal aortic aneurysms is associated with cellular and molecular alterations prefacing wall deterioration and rupture. J Nucl Med 54 (2013), 1740–1747.
31. 31 Tegler, G., Sorensen, J., Ericson, K., Bjorck, M., Wanhainen, A., 4D-PET/CT with [(11)C]-PK11195 and [(11)C]-(D)-deprenyl does not identify the chronic inflammation in asymptomatic abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 45 (2013), 351–356.
32. 32 Richards, J.M., Semple, S.I., MacGillivray, T.J., Gray, C., Langrish, J.P., Williams, M., et al. Abdominal aortic aneurysm growth predicted by uptake of ultrasmall superparamagnetic particles of iron oxide: a pilot study. Circ Cardiovasc Imaging 4 (2011), 274–281.
33. 33 McBride, O.M., Berry, C., Burns, P., Chalmers, R.T., Doyle, B., Forsythe, R., et al. MRI using ultrasmall superparamagnetic particles of iron oxide in patients under surveillance for abdominal aortic aneurysms to predict rupture or surgical repair: MRI for abdominal aortic aneurysms to predict rupture or surgery-the MA(3)RS study. Open Heart, 2, 2015, e000190.
34. 34 Golledge, J., Tsao, P.S., Dalman, R.L., Norman, P.E., Circulating markers of abdominal aortic aneurysm presence and progression. Circulation 118 (2008), 2382–2392.
35. 35 Vega de Ceniga, M., Esteban, M., Barba, A., Estallo, L., Blanco-Colio, L.M., Martin-Ventura, J.L., Assessment of biomarkers and predictive model for short-term prospective abdominal aortic aneurysm growth-a pilot study. Ann Vasc Surg 28 (2014), 1642–1648.
36. 36 Golledge, J., Muller, R., Clancy, P., McCann, M., Norman, P.E., Evaluation of the diagnostic and prognostic value of plasma D-dimer for abdominal aortic aneurysm. Eur Heart J 32 (2011), 354–364.
37. 37 Lindholt, J.S., Jorgensen, B., Fasting, H., Henneberg, E.W., Plasma levels of plasmin-antiplasmin-complexes are predictive for small abdominal aortic aneurysms expanding to operation-recommendable sizes. J Vasc Surg 34 (2001), 611–615.
38. 38 Golledge, J., Norman, P.E., Current status of medical management for abdominal aortic aneurysm. Atherosclerosis 217 (2011), 57–63.
39. 39 Propanolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg 35 (2002), 72–79.
40. 40 Lindholt, J.S., Henneberg, E.W., Juul, S., Fasting, H., Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol 18 (1999), 52–57.
41. 41 Wilmink, A.B., Hubbard, C.S., Day, N.E., Quick, C.R., Effect of propranolol on the expansion of abdominal aortic aneurysm: a randomised study. Br J Surg, 87, 2000, 499.
42. 42 Meijer, C.A., Stijnen, T., Wasser, M.N., Hamming, J.F., van Bockel, J.H., Lindeman, J.H., et al. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med 159 (2013), 815–823.
43. 43 Sillesen, H., Eldrup, N., Hultgren, R., Lindeman, J., Bredahl, K., Thompson, M., et al. Randomized clinical trial of mast cell inhibition in patients with a medium-sized abdominal aortic aneurysm. Br J Surg, 102, 2015, 1295.
44. 44 Bicknell CD, Kiru G, Falaschetti E, Powell JT, Poulter NR; AARDVARK Collaborators. An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK) [published online ahead of print July 1, 2016]. Eur Heart J http://dx.doi.org/10.1093/eurheartj/ehw257.
45. 45 Morris, D.R., Cunningham, M.A., Ahimastos, A.A., Kingwell, B.A., Pappas, E., Bourke, M., et al. TElmisartan in the management of abDominal aortic aneurYsm (TEDY): the study protocol for a randomized controlled trial. Trials, 16, 2015, 274.
46. 46 Wanhainen A. The efficacy of ticagrelor on abdominal aortic aneurysm expansion. Available at: https://clinicaltrials.gov/ct2/show/NCT02070653?term=abdominal+aortic+aneurysm&rank=42. Accessed February 10, 2016.
47. 47 Allaire E. Cyclosporine A in patients with small diameter abdominal aortic aneurysm. Available at: https://clinicaltrials.gov/ct2/show/NCT02225756?term=abdominal+aortic+aneurysm&rank=63. Accessed February 10, 2016.
48. 48 Dong-Hoon C. Comparison of beta blocker versus angiotensin receptor blocker for suppression of aneurysm expansion in patients with small abdominal aortic aneurysm and hypertension (BASE Trial). Available at https://clinicaltrials.gov/ct2/show/NCT01904981?term=abdominal+aortic+aneurysm&rank=67. Accessed February 10, 2016.
49. 49 Baxter BT, Curci J, Matsumura J, Terrin ML. Non-invasive treatment of abdominal aortic aneurysm clinical trial. Available at: https://clinicaltrials.gov/ct2/show/NCT01756833?term=abdominal+aortic+aneurysm&rank=68. Accessed February 10, 2016.
50. 50 Bowen, J.M., Connolly, H.M., Of Marfan's syndrome, mice, and medications. N Engl J Med 371 (2014), 2127–2128.
51. 51 Shi, G.P., Lindholt, J.S., Mast cells in abdominal aortic aneurysms. Current Vasc Pharmacol 11 (2013), 314–326.
52. 52 Liu, J., Daugherty, A., Lu, H., Angiotensin II and abdominal aortic aneurysms: an update. Curr Pharm Des 21 (2015), 4035–4048.
53. 53 Hackam, D.G., Thiruchelvam, D., Redelmeier, D.A., Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 368 (2006), 659–665.
54. 54 Sweeting, M.J., Thompson, S.G., Brown, L.C., Greenhalgh, R.M., Powell, J.T., Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg 52 (2010), 1–4.
55. 55 Parr, A., McCann, M., Bradshaw, B., Shahzad, A., Buttner, P., Golledge, J., Thrombus volume is associated with cardiovascular events and aneurysm growth in patients who have abdominal aortic aneurysms. J Vasc Surg 53 (2011), 28–35.
56. 56 Owens, A.P. 3rd, Edwards, T.L., Antoniak, S., Geddings, J.E., Jahangir, E., Wei, W.Q., et al. Platelet inhibitors reduce rupture in a mouse model of established abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 35 (2015), 2032–2041.
57. 57 Wang, Y., Ait-Oufella, H., Herbin, O., Bonnin, P., Ramkhelawon, B., Taleb, S., et al. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest 120 (2010), 422–432.
58. 58 Dai, J., Michineau, S., Franck, G., Desgranges, P., Becquemin, J.P., Gervais, M., et al. Long term stabilization of expanding aortic aneurysms by a short course of cyclosporine A through transforming growth factor-beta induction. PLoS One, 6, 2011, e28903.
59. 59 Tilson, M.D., Similarities of an autoantigen in aneurysmal disease of the human abdominal aorta to a 36-kDa microfibril-associated bovine aortic glycoprotein. Biochem Biophys Res Commun 213 (1995), 40–43.
60. 60 Lu, S., White, J.V., Lin, W.L., Zhang, X., Solomides, C., Evans, K., et al. Aneurysmal lesions of patients with abdominal aortic aneurysm contain clonally expanded T cells. J Immunol 192 (2014), 4897–4912.
61. 61 Yin, M., Zhang, J., Wang, Y., Wang, S., Bockler, D., Duan, Z., et al. Deficient CD4+CD25+ T regulatory cell function in patients with abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 30 (2010), 1825–1831.
62. 62 Sharma, A.K., Lu, G., Jester, A., Johnston, W.F., Zhao, Y., Hajzus, V.A., et al. Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment. Circulation 126:11 Suppl 1 (2012), S38–S45.
63. 63 Hackmann, A.E., Rubin, B.G., Sanchez, L.A., Geraghty, P.A., Thompson, R.W., Curci, J.A., A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J Vasc Surg 48 (2008), 519–526.
64. 64 Lindeman, J.H., Abdul-Hussien, H., van Bockel, J.H., Wolterbeek, R., Kleemann, R., Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 119 (2009), 2209–2216.